Prothena (NASDAQ:PRTA - Free Report) had its target price decreased by Royal Bank of Canada from $24.00 to $20.00 in a research report sent to investors on Friday morning,Benzinga reports. Royal Bank of Canada currently has a sector perform rating on the biotechnology company's stock.
Several other brokerages have also weighed in on PRTA. Bank of America reduced their price objective on Prothena from $26.00 to $22.00 and set a "neutral" rating for the company in a report on Thursday, December 19th. Chardan Capital reiterated a "buy" rating and set a $40.00 price target on shares of Prothena in a research note on Friday. Oppenheimer boosted their price objective on Prothena from $58.00 to $62.00 and gave the company an "outperform" rating in a research note on Friday, February 7th. HC Wainwright reaffirmed a "buy" rating and set a $48.00 price objective on shares of Prothena in a report on Friday. Finally, StockNews.com downgraded shares of Prothena from a "hold" rating to a "sell" rating in a research note on Tuesday, November 19th. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $45.83.
Read Our Latest Research Report on PRTA
Prothena Trading Down 3.9 %
Shares of NASDAQ:PRTA traded down $0.60 during midday trading on Friday, reaching $14.63. The company had a trading volume of 387,703 shares, compared to its average volume of 376,889. Prothena has a 52-week low of $11.70 and a 52-week high of $31.03. The company's 50 day moving average price is $14.38 and its 200 day moving average price is $16.73. The stock has a market cap of $787.23 million, a P/E ratio of -6.36 and a beta of 0.08.
Prothena (NASDAQ:PRTA - Get Free Report) last released its earnings results on Thursday, February 20th. The biotechnology company reported ($1.08) earnings per share for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.06). Prothena had a negative net margin of 90.50% and a negative return on equity of 22.67%. The company had revenue of $2.12 million during the quarter, compared to analysts' expectations of $7.53 million. Research analysts forecast that Prothena will post -4.04 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several large investors have recently added to or reduced their stakes in the stock. Orion Portfolio Solutions LLC increased its position in shares of Prothena by 4.4% during the third quarter. Orion Portfolio Solutions LLC now owns 17,531 shares of the biotechnology company's stock valued at $293,000 after buying an additional 739 shares during the period. Virtus ETF Advisers LLC grew its stake in Prothena by 19.3% during the fourth quarter. Virtus ETF Advisers LLC now owns 5,148 shares of the biotechnology company's stock valued at $71,000 after acquiring an additional 833 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in Prothena by 10.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,409 shares of the biotechnology company's stock valued at $158,000 after acquiring an additional 1,065 shares in the last quarter. Rhumbline Advisers increased its holdings in Prothena by 1.8% during the 4th quarter. Rhumbline Advisers now owns 67,115 shares of the biotechnology company's stock worth $930,000 after acquiring an additional 1,175 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Prothena by 6.0% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 27,269 shares of the biotechnology company's stock worth $381,000 after purchasing an additional 1,551 shares in the last quarter. Institutional investors own 97.08% of the company's stock.
About Prothena
(
Get Free Report)
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.
Featured Stories
Before you consider Prothena, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prothena wasn't on the list.
While Prothena currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
